PR Newswire
07 Feb 2023, 08:30 GMT+10
MELBOURNE, Australia, Feb. 7, 2023 /PRNewswire/ -- Hinova Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focusing on developing novel therapeutics for cancers and metabolic diseases, recently announced that the U.S. Food and Drug Administration (FDA) has cleared the company's investigational new drug application (IND) for its innovative drug HP518, an oral chimeric degrader targeting androgen receptor (AR) for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
HP518 is currently in Phase I clinical trials in Australia. The open-label study approved by FDA will assess the safety, pharmacokinetics, and anti-tumor activity of HP518.
"HP518 is a novel drug expected to address the unmet clinical needs of prostate cancer treatment," said Yuanwei Chen, Ph.D., President and CEO of Hinova. "The available study results of HP518 strengthen our confidence that HP518 is a potentially new treatment for drug resistant prostate cancer. We are making full efforts to advance the clinical study, hoping HP518 will provide more clinical benefits to patients worldwide in the future."
HP518 has been discovered and developed through Hinova's targeted protein degradation drug discovery platform. It has the potential to overcome the drug resistance of prostate cancer that is due to some specific AR mutations. AR is a validated therapeutic target to treat prostate cancer. During the treatment of prostate cancer, drug resistance becomes inevitable due to multiple mechanisms, including AR amplification or mutations, etc. In preclinical studies, HP518 showed excellent selectivity and degradation activity against wild type AR and some specific AR mutants that are resistant to enzalutamide. HP518 also demonstrated excellent antitumor efficacy in xenograft mouse models.
About Hinova
Hinova is an international and clinical-stage biopharmaceutical company engaged in the development of innovative deuterated and chimeric degraders for cancers and metabolic diseases. The company has established a targeted protein degradation drug discovery platform, which allows Hinova to screen for protein degradation activity rapidly and to accomplish efficient design and optimization of chimeric degraders. Furthermore, Hinova has profound experience in chemical manufacturing control (CMC) of Chimeric degrader compounds. For more information, please visit http://www.hinovapharma.com/en/.
Get a daily dose of Asia Pacific Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Asia Pacific Star.
More InformationMANILA, Philippines: Under a defense agreement with the U.S., four new military bases will be located in various parts of ...
WASHINGTON D.C.: The US Commerce Department has proposed new laws aimed at preventing China and other countries deemed of concern ...
TAIPEI, Taiwan: In an effort to ease tensions between Taiwan and China, former Taiwanese President Ma Ying-jeou will visit Beijing ...
MANILA, Philippines: An underwater robot from Japan has located a leaking fuel tanker, MT Princess Empress, which sank off the ...
Bangkok [Thailand], March 26 (ANI): Thai Prime Minister Prayuth Chan-ocha has accepted his party's nomination and will stand for re-election ...
© Provided by Xinhua COLOMBO, March 26 (Xinhua) -- Sri Lanka aims to attract around 1.5 million tourists this year, ...
LONDON, England: Reuters has reported that struggling Virgin Orbit, owned by billionaire Richard Branson, is nearing a $200-million investment deal ...
NEW YORK CITY, New York: To comply with the requirements of the "Made in America" laws, a $7.5 billion federal ...
LONDON, England: During a Bloomberg conference held in London this week, Luke Ellis, CEO of hedge fund Man Group, said ...
NEW YORK, New York - Wall Street jumped on Friday, although gains were modest after bank shares in Europe came ...
LOS ANGELES, California: Some 30,000 education workers in Los Angeles, backed by teachers, went on a three-day strike, canceling school ...
LONDON, England: Despite rising air fares, a potential global economic recession and risks of gridlock at some airports in Europe ...